Stress hyperglycemia ratio and long‐term prognosis in patients with acute coronary syndrome: A multicenter, nationwide study
Guyu Zeng, Ying Song, Zheng Zhang, Jingjing Xu, Zhenyu Liu, Xiaofang Tang, Xiaozeng Wang, Yan Chen, Yongzhen Zhang, Pei Zhu, Xiaogang Guo, Lin Jiang, Zhifang Wang, Ru Liu, Qingsheng Wang, Yi Yao, Yingqing Feng, Yaling Han, Jinqing Yuan
Abstract
BACKGROUND: Stress hyperglycemia ratio (SHR), a novel biomarker of stress hyperglycemia, was proved to be a reliable predictor of short-term adverse outcomes in patients with acute coronary syndromes (ACS). However, its impact on long-term prognosis remained controversial. METHODS: A total of 7662 patients with ACS from a large nationwide prospective cohort between January 2015 and May 2019 were included. SHR was calculated by the following formula: SHR = admission glucose (mmol/L)/(1.59 × HbA1c [%]-2.59). The primary end point was a major adverse cardiovascular event (MACE) during follow-up, a composite of all-cause death, myocardial infarction, and unplanned revascularization. The second end point was the separate components of the primary end points. RESULTS: During a median follow-up of 2.1 years, 779 MACE events occurred. After multivariable adjustment, ACS patients with the highest SHR tertile were significantly associated with increased long-term risks of MACE (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.24-1.88), all-cause death (HR 1.80, 95% CI 1.29-2.51) and unplanned revascularization (HR 1.44, 95% CI 1.09-1.91). Although significant associations between the highest SHR tertile and risks of MACE and all-cause death were assessed in both diabetic and nondiabetic patients, the patterns of risk were different in these two groups. CONCLUSION: Elevated SHR was independently associated with a higher risk of long-term outcomes irrespective of diabetic status, suggesting that SHR was a potential biomarker for risk stratification after ACS.